Home
overview

The early days of medicine were very similar to point-of-care in that healthcare was delivered in the patients home. The shift towards specialised laboratories and healthcare centres led to a more curative approach to medicine The rapid advancement in technology over the last 20 years has caused this dynamic to shift towards a non-laboratory setting with the ability to perform rapid and accurate diagnostic tests on a patients condition. The shift from curative to preventative approaches to Point of Care can now be enabled by rapid gene sequencing techniques and early detection through microfluidic devices and lab-on-a-chip technology.

So what does the future hold for POC? Join SMi as we take a look at the future advancements within the field of Point of Care Diagnostics and look to identify POC trends and market opportunities in this ever changing and dynamic field of medicine.

  • Identify key industry trends and market opportunities
  • Discover new technological applications and the latest advances in device technology
  • Learn how to overcome potential barriers to commercialisation of a new technology
  • Gain an insight into the future of POC technologies
  • Understand the benefits of non-invasive patient testing and how new profiling technologies lead to a better personalised treatment approach

SMi's 10th annual Point of Care Diagnostics Conference is a must attend for the following people:

Business Development Managers

Chief Scientific Officers

Hospital CEO's

Physicians

Pharmacists

Clinical Scientists

Product Development Managers

Chief Techinical Officers

Directors/Heads/ VP's Point of Care

Policy makers

Venture Capitalist

 

A B A France; BD Medical - Pharmaceutical; BIVDA; Brunel University; Carclo Technical Plastics (Mitcham) Ltd; Diasys Diagnostic Systems; DuPont Teijin Films UK Ltd; EPFL; Exacsys; Genomic Healthcare Strategies; Hamad Medical Corporation; Hôpital La Timone; Imperial College London; Institute of Microbiology; Inventages; NHS National Innovation Centre; Norgine; Novescia Network of Clinical Laboratories; PA Consulting Group; Patients Know Best; Qiagen; Quorum Consulting; Radiometer Denmark A / S; Roche Chemische Unternehmungen AG; Roche Diagnostics GmbH; Royal Free Hospital; South Tyneside Primary Care Trust; Technology Strategy Board; Thinxxs G Mb H; UL International GmbH; University Of Antwerp; University Of Twente; University of Ulster; Vivacta Ltd; Werfen Group;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

David Huckle

David Huckle, Chief Executive, Adams Business Associates

9:10 Is POCT the future of Diagnostics?

  • POCT not a technology but has technology demands
  • Applications of POCT and Market segments
  • Market position and status of POCT
  • Market drivers and regulations & reimbursement
  • POCT as more than IVD's
  • David Huckle

    David Huckle, Chief Executive, Adams Business Associates

    9:50 Implementing effective POCT services strategically

    David  Wells

    David Wells, Lead Laboratory Manager and Lead Healthcare Scientist, Great Ormond Street Hospital

    10:30 Morning Coffee

    11:00 Sensor technologies for mHealthcare

    Christopher Lowe

    Christopher Lowe, Director of the Institute of Biotechnology, Cambridge University

    11:40 Point of care testing and clinical outcomes

    Maurice O'Kane

    Maurice O'Kane, Consultant, Altnagelvin Hospital

  • The impact of POCT on operational outcomes
  • The impact of POCT on financial outcomes
  • POCT as 'disruptive technology'
  • The impact of POCT on patient clinical outcomes
  • 12:20 Networking Lunch

    13:20 Patient- controlled records for new POCT business models

    Mohammad Al-Ubaydli

    Mohammad Al-Ubaydli, CEO, Patients Know Best

  • Putting patient in control of the data allows service redesign for better clinical workflow and new business models
  • CASE STUDY: NHS Diabetes clinic with POCT of HbA1c results feeding directly into hospital institutional and patient's personal record
  • CASE STUDY: Private Laboratory clinic with 50 million tests per year able to accept POCT t new NHS sites
  • CASE STUDY: Faecal occult blood testing in patients homes combined with self assessment protocols allowing patient to decide when to conatct hospital
  • CASE STUDY: iPhone glucose monitors allowing patients to share data with clinical team in between appointments for titrating insulin regime
  • 14:00 Rapid Magneto Immunoassay

    Richard Luxton

    Richard Luxton, Director of the Institute of Bio-Sensing Technology, University Of The West Of England Bristol

  • Principle of rapid magneto immunoassay
  • Instrumentation and sample interface
  • Application areas of rapid magneto immunoassay
  • 14:40 Afternoon Tea

    15:10 The Development of an Award Winning Point of Care Support Team across the NHS Northern Region

    Tony Gibson

    Tony Gibson, Scientific Director, Gateshead Healthcare Nhs Trust

  • Building relationships with higher education establishments and industry partners
  • Positioning 'near patient' services to benefit emerging NHS initiatives including health checks
  • Pulling the pieces together - fit for the future

     

  • 15:50 A regional program for POCT Services- More is different

    Per Simonsson

    Per Simonsson, Professor, University Hospital MAS

  • Advantages and challenges of a regional POCT System
  • Key aspects are IT, Transferability, preanalytics
  • Multi-level relationships with clinical department
  • More is different
  • 16:30 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Phil Lefebvre

    Phil Lefebvre, Sr. Manager, Technical Assessment,

    9:10 The Future of Decentralised/ POC Molecular Diagnostics

    Phil Lefebvre

    Phil Lefebvre, Sr. Manager, Technical Assessment,

  • Can molecular testing be used as a viable POCT?
  • What is the feasibility of performing these tests outside of the laboratory?
  • How accurate are these tests and what are the current and future applications?
  • 9:50 Molecular Diagnostics in Personalised Medicine

    Nigel Sansom

    Nigel Sansom, Senior Manager, NHS National Innovation Centre

  • Molecular Diagnostics tody
  • The market and current market dirvers
  • The confluence of nanobiosensors, molecular semantics and synthetic biology
  • 10:30 Morning Coffee

    11:00 Metal Nanoparticles for optical imaging in medicine

    Jose Costa-Fernandez

    Jose Costa-Fernandez, Vice Dean of the Faculty of Chemistry, University of Oviedo

  • Metal nanoparticles for cellular labelling, In vivo  and deep tissue imaging
  • Nanoparticles and FRET for optical imaging
  • Potential toxicity associated with long- term exposure of live cells to particular luminescent nanoparticles 
  • 11:40 Understanding the need for point-of-care tests in low-resource settings

    Roger Peck

    Roger Peck, Research Scientist, PATH

  • Defining the specification of HIV self test appropriate use in Sub-Saharan Africa
  • Assessing utility of self test features in naive testing populations
  • 12:20 Networking Lunch

    13:20 Point of Care Testing for Personalised Medicine for Infectious diseases

  • Rapid detection of infectious diseases
  • Tailoring antibiotic treatment to patient and pathogen
  • Understanding the biomarkers
  • Till Bachmann

    Till Bachmann, COO, Head of Biochip Research, University of Edinburgh

    14:00 Tuberculosis: Working towards diagnostic solutions

    Penny Wilson

    Penny Wilson, Lead Specialist, Detection and Identification Of Infectious Agents, Technology Strategy Board

  • Tuberculosis, the challenge
  • The development of novel POC diagnostics
  • The Global dimension
  • 14:40 Afternoon Tea

    15:10 POCT in Ambulance Care

    Brian Winn

    Brian Winn, Partner, Bitecic

  • New models of Ambulance services offer new opportunities for POCT
  • What does a paramedic need to know on arrival at a scene?
  • What POC Tests would speed decision-making for front line medics?
  • What do they expect from these devices
  • Rapid test results lead to better informed treatment therapies at the scene
  • Opportunities arising from future technologies for front line healthcare professionals
  • 15:50 Understanding critical factors for the success of new point of care diagnostics and making the most of established technologies

    John Rippeth

    John Rippeth, Principal Consultant, PA Consulting Group

  • Reconfiguration of existing technologies for new applications to ensure a better patient outcome
  • Ensuring that new technologies address more than just performance benefits
  • Understanding teh care pathway to better implement diagnostic testing
  • 16:30 Rapid molecular diagnostics for Point-of-Care

    John Clarkson

    John Clarkson, Chief Executive, ATLAS GENETICS LTD

  • Rapid integrated molecular diagnostics technologies are becoming commercially available
  • These have the potential to positively impact patient care
  • Application areas include infectious disease, coagulation and companion diagnostics
  • This talk will discuss recent advances in this area, using the Atlas io™ system as an example, with specific focus on applications in diagnosis of sexually transmitted infections

     

  • 17:10 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Penny Wilson

    Penny Wilson

    Lead Specialist, Detection and Identification Of Infectious Agents, Technology Strategy Board
    Phil Lefebvre

    Phil Lefebvre

    Sr. Manager, Technical Assessment,
    Till Bachmann

    Till Bachmann

    COO, Head of Biochip Research, University of Edinburgh
    Tony Gibson

    Tony Gibson

    Scientific Director, Gateshead Healthcare Nhs Trust

    Brian Winn

    Partner, Bitecic
    Brian Winn

    Christopher Lowe

    Director of the Institute of Biotechnology, Cambridge University
    Christopher Lowe

    David Wells

    Lead Laboratory Manager and Lead Healthcare Scientist, Great Ormond Street Hospital
    David  Wells

    David Huckle

    Chief Executive, Adams Business Associates
    David Huckle

    John Clarkson

    Chief Executive, ATLAS GENETICS LTD
    John Clarkson

    John Rippeth

    Principal Consultant, PA Consulting Group
    John Rippeth

    Jose Costa-Fernandez

    Vice Dean of the Faculty of Chemistry, University of Oviedo
    Jose Costa-Fernandez

    Maurice O'Kane

    Consultant, Altnagelvin Hospital
    Maurice O'Kane

    Mohammad Al-Ubaydli

    CEO, Patients Know Best
    Mohammad Al-Ubaydli

    Nigel Sansom

    Senior Manager, NHS National Innovation Centre
    Nigel Sansom

    Penny Wilson

    Lead Specialist, Detection and Identification Of Infectious Agents, Technology Strategy Board
    Penny Wilson

    Per Simonsson

    Professor, University Hospital MAS
    Per Simonsson

    Phil Lefebvre

    Sr. Manager, Technical Assessment,
    Phil Lefebvre

    Richard Luxton

    Director of the Institute of Bio-Sensing Technology, University Of The West Of England Bristol
    Richard Luxton

    Roger Peck

    Research Scientist, PATH
    Roger Peck

    Till Bachmann

    COO, Head of Biochip Research, University of Edinburgh
    Till Bachmann

    Tony Gibson

    Scientific Director, Gateshead Healthcare Nhs Trust
    Tony Gibson

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.